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Summary
We describe a multicopy gene suppression screen of
drug sensitivity in Saccharomyces cerevisiae that fa-
cilitates the identification of cellular targets of small
molecules. An array of yeast transformants harboring
a multicopy yeast genomic library was screened for
resistance to growth inhibitors. Comparison of array
growth patterns for several such inhibitors allowed
the differentiation of general and molecule-specific
genetic suppressors. Specific resistance to phenyl-
aminopyrimidine (1), an inhibitor identified from a ki-
nase-directed library, was associated with the over-
expression of Pkc1 and a subset of downstream
kinases. Components of two other pathways (phero-
mone response/filamentous growth and Pho85 kinase)
that genetically interact with the PKC1 MAPK signaling
cascade were also identified. Consistent with the sup-
pression screen, inhibitor 1 bound to Pkc1 in yeast
cell lysate and inhibited its activity in vitro. These re-
sults demonstrate the utility of this approach for the
rapid deconvolution of small-molecule targets.
Introduction
Phenotypic or pathway-specific high-throughput screens
of small-molecule libraries are often used for the dis-
covery of small-molecule effectors or inhibitors of cellu-
lar processes. However, the subsequent identification
of the small-molecule targets can be quite challenging.
The budding yeast Saccharomyces cerevisiae has been
broadly employed for drug target identification and
mechanism-of-action studies. It is a model organism
representative of simple eukaryotes, but has only
slightly greater genetic complexity than bacteria
(w6,200 open reading frames; ORFs) and its genome
can be easily manipulated [1, 2]. Significantly, about
30% of known genes implicated in human disease have
yeast orthologs [3]. Target identification and validation
in yeast have been especially useful in the case of anti-
proliferative agents [4], where the potential small-mole-
cule targets are often components of highly conserved
cell division or DNA repair machinery.
In recent years, various yeast genomics- and proteo-*Correspondence: supek@gnf.orgmics-based target identification strategies have been
developed [5, 6]. In particular, the availability of a com-
prehensive collection of gene deletion strains [7, 8] has
expanded the utility of yeast in small-molecule target
deconvolution. Screens employing induced haploinsuf-
ficiency (the diploid strain heterozygous at the drug
target locus being more sensitive to the small molecule
than the wild-type strain) have been carried out with
gene deletion strains in order to identify or confirm the
targets of tunicamycin [9] and other drugs [10, 11]. An-
other approach involves comparison of gene expres-
sion profiles of drug-treated cells with a compendium
of expression profiles derived from a large set of gene
knockout strains. This method was used to identify a
novel target of the commonly used drug dyclonine [12].
And yet another approach utilized the global pattern
of genetic interactions obtained from synthetic genetic
array (SGA) analysis [13] or synthetic lethality analysis
by microarray (SLAM) [14]. SGA and SLAM allow for
screening of mutations that exhibit synthetic lethal in-
teractions either by crossing a query mutation with ar-
rayed deletion mutants (SGA) or by introducing a query
mutation via integrative transformation into a haploid
deletion pool (SLAM). Based on the hypothesis that the
drug hypersensitivity profile and the genetic interaction
profile should match if the query mutation is in the drug
target encoding gene, the mechanism of action of a
small molecule can be inferred by comparing the
growth defect pattern of haploid deletion strains after
drug exposure with the “fingerprint” genetic interaction
profile [15].
A complementary approach to the screens described
above, which involve gene deletion strains, is a
multicopy suppression screen for genes that confer re-
sistance to an inhibitor upon overexpression [1, 2]. This
screen is based on the principle that cells which ex-
press increased levels of a small-molecule target
should tolerate higher drug levels. Such a screen is car-
ried out by the introduction of a yeast chromosomal
library harbored on a multicopy vector into the wild-
type yeast strain with subsequent examination of indi-
vidual transformants for resistance to the inhibitor. The
molecular targets for various known antifungals, such
as tunicamycin [16], ketoconazole [17], and soraphen
[18], have been identified in this fashion.
The main limitation of the above approaches to drug
target identification is that only a subset of potentially
interesting compounds has a growth-inhibitory pheno-
type in yeast. This is caused partly by a lower perme-
ability of yeast cells to small molecules as compared to
mammalian cells, partly by the nonessential nature of
equivalent yeast targets, and partly by the absence of
such mammalian targets in yeast. In spite of these
limitations, approaches utilizing budding yeast repre-
sent a powerful tool for drug target identification.
Here we report a variation of a gene dosage resis-
tance screen that is amenable to a high-throughput for-
mat by using arrays of transformed S. cerevisiae
strains. Such an approach allows target identification
for small molecules that are active in mammalian cells
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Tplied this method to the identification of targets of a
small molecule derived from cellular screens of kinase- r
tdirected combinatorial libraries [19]. Protein kinases re-
present an important class of drug targets because b
3they are involved in the regulation of various cellular
functions (e.g., proliferation activation or apoptosis) g
t[20] and aberrant kinase activity has been linked to





Small-Molecule Screen for Growth Inhibitors
A small library of w1000 kinase-directed heterocyclic
small molecules [19] was screened for inhibitors of
growth using standard yeast strain YPH500. The screen
was carried out in a 384-well format on soft agar and
plates were visually inspected for growth inhibition. A
number of active compounds were identified that in-
hibited yeast growth with IC50 values less than 20 M.
The structure of one of these molecules, N-(3-chlo-
rophenyl)-4-(4-pyridinyl)-2-pyrimidinamine (1) (IC50 w5
M; Figure 1) [22], shares the phenylaminopyrimidine
(PAP) scaffold with the anticancer kinase inhibitors STI-
571 (Gleevec, 2, Bcr-Abl inhibitor) [23] and CGP60474
(3, CDK1/CDK2 inhibitor) [24], and was selected for
testing the target identification strategy by dosage sup-
pression of drug sensitivity.
Generation of Overexpression Library
The YPH500 strain was transformed with the yeast ge-
nomic DNA library constructed in the multicopy YEp13
plasmid (average insert size, 5 kb) [25]. In total, 7296
randomly picked transformants were arrayed in 384-
well plates (19 plates). To determine the frequency with
which a typical gene is present in the array, the trans-
formants were plated on minimal media lacking either
histidine or tryptophan. Because YPH500 strain har-
bors inactivated trp1 and his3 genes, it cannot grow on
either medium. However, the genomic DNA of the yeast
strain from which the library was constructed has the
functional TRP1 and HIS3 genes. Thus, the presence of
a plasmid in the library that contains one of these two
genes in YPH500 strain will restore growth to a trans-
Fformant on medium lacking the respective amino acid.
AIn total, the assembled array of transformants con-
−
tained three Trp+ and four His+ independent clones, in- i
dicating that a typical library gene is represented in the p
Darray multiple times.Figure 1. Structures of PAP Compounds 1
(This Study), 2 (STI-571), and 3 (CGP60474)creen for Suppressors of Growth Inhibition
o screen for suppressors of growth inhibition by py-
imidine 1, a minimal inhibitor concentration was used
hat prevented the formation of control colonies (har-
oring YEp13 vector without an insert) in the course of
-day cultivation. The arrayed transformants were first
rown in 384-well plates and then stamped with a pin-
ool onto −Leu agar in the absence of inhibitor to as-
ess viability of the transformed strains (Figure 2A), and
nto agar containing compound 1 at 15 M (four 384-
ell plates were replicated onto one agar plate). The
esistant colonies (Figure 2B) were first selected and
hen analyzed by determining the sequence of the vec-igure 2. Photographs of a Representative Plate from the Array
total of 1536 transformed yeast strains were replicated onto each
Leu agar plate and cultivated for 3 days (A) in the absence of
nhibitor, (B) in the presence of inhibitor 1 (15 M), and (C) in the
resence of a structurally distinct inhibitor (see Supplemental
ata). Nonspecific suppressors are indicated with white arrows.
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database comparison. To eliminate false positives due
to plasmid-independent genetic variations among the
individual transformants, only the genes recovered
from at least two colonies in a particular small-molecule
screen were considered. Furthermore, because many
plasmids harbor several full-length ORFs, the exact lo-
calization of the resistance-conferring gene requires
deletion analysis of inserts and reexamination of the
resistant phenotype for the deletion constructs. There-
fore, to avoid such laborious analysis, we considered
only those genes that were recovered in a particular
compound screen multiple times and in such sequence
contexts that allowed unequivocal assignment of resis-
tance to a single gene.
Genes, which conferred resistance to not only com-
pound 1 but also to several other inhibitors identified in
the small-molecule screens (see Supplemental Figure
S1), were classified as nonspecific suppressors (com-
pare Figures 2B and 2C). These included drug pump
gene PDR3, ribose-phosphate pyrophosphokinase gene
PRS4 (catalyzing the rate-limiting step in the synthesis
of the precursor molecule for the biosynthesis of nucle-
otides, tryptophan, and histidine), L-myo-inositol-1-
phosphate synthase gene INO1 (catalyzing the rate-lim-
iting step in the biosynthesis of inositol), and poly(A)
binding protein gene PAB1 (essential function in protein
translation). Because these genes rescue growth inhibi-
tion by structurally distinct compounds, the mechanism
of suppression by these genes is likely not related to
the specific mechanism of action of compound 1.
Suppressors that selectively rescued growth inhibi-
tion by compound 1 were categorized into three
classes (Table 1). The first group comprises members
of the PKC1-MPK1 MAP kinase signaling pathway,
which plays an essential role in several processes in-
cluding bud formation, polarized cell growth, and main-
tenance of cell wall integrity during environmental
stress [26]. In addition to PKC1, two other kinase-
encoding genes were recovered in the screen: BCK1
(MAPKKK) and MKK2 (MAPKK); both act downstream
in this pathway. The second class of suppressors con-
tains a single gene, CLG1. Clg1 is one of ten cyclins
(generally classified into two subfamilies) associated
with Pho85 CDK and belongs to the Pcl1/Pcl2 subfam-
ily, which is believed to play a role in polarized cell
growth [27]. Interestingly, a pcl1D pcl2D double dele-
tion is synthetically lethal when combined with bck1D
or mpk1D (MAPK, PKC1-MPK1 signaling cascade) mu-
tations [28]. This indicates that both pathways (Pkc1
and Pho85) fulfill partially redundant functions. Pho85Table 1. Genes from Overexpression Screen Conferring Resistance to Compound 1
Specificity Category Hitsb
Specific PKC1 MAPK pathway PKC1 (4), BCK1 (2), MKK2 (3)
Cell cycle CLG1 (5)
Filamentous growtha KSS1 (4), STE5 (3), STE7 (3)
Nonspecific Drug pump PDR3 (4)
Biosynthetic genes PAB1 (7), PRS4 (7), INO1 (3)
a Components are also involved in the pheromone response pathway.
b Numbers in parentheses indicate the number of independent resistant colonies harboring a given gene on plasmid insert.is nonessential but also capable of serving as an alter-
native to Cdc28, the main (and essential) CDK for cell
cycle progression in yeast [29, 30]. The last class of
suppressors included a subset of genes involved in the
pheromone response/filamentous growth MAP kinase
signaling pathway [31]. In addition to the scaffolding
protein Ste5, two additional kinases—Ste7 and Kss1—
rescued growth inhibition by compound 1. Kss1, one of
the two downstream effectors of this signaling cas-
cade, is known to regulate the transcription of dozens
of genes that contribute to pheromone response/fila-
mentous growth [32, 33]. A prominent feature of Kss1
activation is an altered cell cycle and the upregulation
of Cln cyclins (the Cdc28 CDK cyclins) [33, 34]. Similar
to the Pho85 pathway (Clg1), the Cln cyclins are known
to genetically interact with the Pkc1 signaling cascade,
and overexpression of Cln2 suppresses certain pkc1
mutations [35]. Furthermore, pcl1D pcl2D double and
pho85D single mutants are synthetically lethal not only
with mutations in genes of the Pkc1 pathway (see
above), but also when combined with cln1D cln2D mu-
tations [28]. Thus, all three pathways identified in the
screen exhibit extensive genetic interactions with each
other, which further underscores their relevance for the
resistance to compound 1.
Deletion Strain Analysis of Growth Inhibition
In the simplest case, if growth inhibition results from
the biochemical inactivation of a protein by compound
treatment, the target-encoding gene must be essential
for yeast growth. Because PKC1 was the only com-
pound-specific gene recovered in the screen that is
also essential for viability (Table 1), and because the
other identified genes function in two other pathways
known to genetically interact with the Pkc1 signaling
cascade, Pkc1 was considered as the primary target
for compound 1. To test this hypothesis, we first re-
confirmed that transformation of wild-type yeast strain
with multicopy plasmid (YEp13) harboring PKC1 as the
only nonvector ORF increases resistance of the trans-
formed wild-type strain to compound 1 (Figure 3A). It
was also reported that growth defect of a pkc1D yeast
strain can be rescued by increasing the medium osmo-
larity through the addition of high concentrations (1.0 M)
of sorbitol [36]. Consistent with this hypothesis, the in-
hibitory effect of compound 1 was completely elimi-
nated under such growth conditions (Figure 3A). To fur-
ther extend these observations, we examined the
sensitivity to 1 of several viable strains containing gene
deletions in the cell wall integrity signaling pathway
downstream of Pkc1 (pkc1D/PKC1, bck1D, mkk1D,
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58mkk2D, mpk1D, swi4D, and swi6D). Unlike the initial p
cscreens, this experiment showed significant growth of
wild-type strain in the presence of compound 1 already c
cafter 20 hr (Figure 3B). The enhanced growth was likely
to be caused by several factors. First, the number of s
cseeded cells was significantly higher in this experiment
than it was during the screen. Second, yeast cells grew i
cmuch faster in the liquid medium than on agar. And
third, it is possible that compound 1 is a less potent S
Minhibitor of yeast growth under the latter conditions.
Nevertheless, there was significant inhibition of wild- d
atype strain growth by 1 at 15 M concentration (Figure
3B). When treated with compound 1, strains lacking w
bSWI4 or SWI6 (transcription factors downstream of the
Pkc1 signaling cascade) [37] exhibited dramatic growth t
pinhibition (Figures 3B and 3C). This observation is in
agreement with the fact that swi4 and swi6 strains 1
vare synthetically lethal with mutations in the PKC1 MAP
kinase pathway [38, 39] and strongly supports our pro- PFigure 3. Gene Dosage Effects
(A) Effect of overexpression of Pkc1 and the
presence of 1 M sorbitol on yeast growth in
the absence and presence of compound 1
(10 M). Serially diluted stocks of the indi-
cated yeast strains were replicated onto
agar plates and incubated for 48 hr.
(B) Growth curves for homozygous (bck1D,
mkk1D, mkk2D, mpk1D, swi4D, swi6D) and
heterozygous (pkc1D/PKC1) diploid deletion
strains in the presence of 1 (15 M) and their
comparison with treated and nontreated
(ctrl) wild-type strain BY4743. All tested
strains grew as well as the wild-type strain
in the presence of equivalent DMSO concen-
tration (data not shown).
(C) Compound 1 IC50 values for the tested
yeast strains as determined in liquid medium.osal that compound 1 inhibits this pathway. Swi6 in
ombination with Swi4 form the heterodimeric SBF
omplex, while Swi6 and Mbp1 constitute the MBF
omplex [40]. Both complexes are involved in the tran-
criptional program that promotes entry into the cell
ycle (START) by activating Cln1,2/Cdc28 (Figure 4). It
s noteworthy that the swi6 strain was the most sus-
eptible to 1 (Figures 3B and 3C), possibly because
wi6 is part of both transcription factor complexes.
utant strains bck1D, mpk1D, and pkc1D/PKC1 also
isplayed increased sensitivity to 1. In contrast, mkk1D
nd mkk2D mutants were not susceptible to treatment
ith 1, which might result from mutual compensation
y Mkk1 and Mkk2 [41]. The synthetic interaction be-
ween the deletion mutations in the downstream com-
onents of PKC1 MAP kinase pathway and compound
indicates that the compound-induced phenotype in-
olves additional pathway(s). It is indeed known that
kc1 also plays a role outside the MAP kinase cascade
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III (Chs3) from the chitosomes to the plasma membrane
[42]. Such extended functions of Pkc1 are also re-
flected in the phenotype of the pkc1D mutant, which is
more severe than that of the downstream mutants of
this MAP kinase pathway. Thus, the results of the gene
deletion experiments are consistent with inhibition of
Pkc1 by compound 1 and Pkc1 being a major cellular
target responsible for the observed growth inhibition.
Biochemical Characterization of Mechanism
of Action
In order to further characterize the molecular targets of
1, affinity chromatography was carried out with yeast
extracts. Resins derived from 1 (resin 4) and an inactive
analog of 1 (resin 5; Figure 5A) were synthesized as
outlined in Figure 5B. 2-Chloroisonicotinic acid (6) was
converted to the vinylogous amide 8 in four steps.
Compound 8 was then reacted with adduct 10 of 3-chlo-
roaniline (9) and cyanamide to afford pyrimidine 11, at
which point the secondary aniline could be methylated
to 12. The linker was introduced by nucleophilic aro-
matic substitution on the pyridine moiety with ethylene-
diamine to give 13 and subsequently modified and ex-
tended by PEGylation. The affinity resins 4 and 5 were
prepared by coupling compound 15 to AffiGel-15 (Bio-
Rad, Hercules, CA) via amide bond formation under
mildly basic conditions (see Supplemental Data for de-
tails). The 2-position of the pyridine ring was chosen as
the site of linker attachment based on docking studies
of the related pyrimidine CGP60474 (3) to the ATP bind-
ing hinge domain of the homologous mammalian ki-
nase CDK2 [24]. The inactive resin 5 differs from 4 by
the presence of an N-methyl group in the PAP skeleton
(Figure 5A), which leads to a substantial loss of activity
(IC50 > 100 M for N-methylated 1). This is consistent
with the above docking study of CGP60474 (3), which
predicts that the NH proton of the PAP-based kinase
inhibitor forms a hydrogen bond with the ATP binding
domain of the kinase. The affinity resins were incubated
with cell extracts and then washed extensively. Pro-
teins retained by the affinity resins were eluted by boil-
ing in SDS, separated by SDS-PAGE, and visualized by
silver staining. Several bands on the protein gel ap-
peared to be specific for the nonmethylated resin 4Figure 4. MAPK Signaling Cascades that Ap-
pear to Play a Role in Rescuing Growth Ar-
rest Induced by Compound 1 (Simplified
Representation)
A pkc1D mutant exhibits a more severe phe-
notype than the deletion mutants in the down-
stream genes and is thought to function in ad-
ditional pathways (indicated by “?”).(Figure 5C). One specific band at 130 kDa was iden-
tified to be Pkc1 by immunoblotting with anti-Pkc1 anti-
body (Figure 5D). Moreover, addition of 100 M com-
pound 1 to the lysates during affinity chromatography
blocked the binding of Pkc1. An in vitro kinase assay
with GST-tagged Pkc1 overexpressed in yeast showed
that compound 1 directly inhibits the enzyme (IC50 0.8
M). In this fluorescence quenching-based assay, the
observed relative fluorescence intensity is inversely
proportional to the extent of phosphorylation (Figure
5E; see Experimental Procedures for details). Further-
more, compound 1 did not inhibit Pkc1 in the presence
of excess ATP, indicating that 1 binds competitively in
the ATP binding site (data not shown). Consistent with
these findings, molecules with a PAP scaffold such as
3 have been reported that bind the mammalian kinase
PKC-α, a homolog of Pkc1 (Table 2) [22, 24].
Other specific protein bands from the affinity pull-
down may represent additional intracellular targets of
compound 1, as the kinase-directed scaffolds are
known to commonly bind multiple kinases [43]. Indeed,
Western blot analysis with an anti-Cdc28 antibody sug-
gested that compound 1 also interacts specifically with
Cdc28 (Figure 5D). This is not surprising given the
structural similarity of 1 to CGP60474 (3), which is an
inhibitor of CDK1/2, a mammalian ortholog of yeast
Cdc28. Inhibition of Cdc28 by compound 1 might also
account for the cell cycle-related suppressors of
growth defects in the dosage suppression screen be-
cause they are closely linked to Cdc28 (Figure 4), as
well as for the high susceptibility to 1 of swi4 and
swi6 deletion strains because Cln3/Cdc28 activates
SBF and MBF [44]. Indeed, compound 1 was shown to
inhibit a number of mammalian CDKs (Table 2). Even
though CDC28 was not identified as a suppressor in
the screen, this might be due to the fact that Cdc28
functions in the complex with cyclins and to increase
its in vivo activity would require simultaneous overex-
pression of both Cdc28 and a cyclin. To examine a pos-
sible role of Cdc28 in growth inhibition by compound
1, we inspected the morphology of compound-treated
yeast cells by light microscopy. Also, we quantified
fractions of yeast cells in different cell cycle stages af-
ter compound treatment by cytometric analysis. Nei-
ther experiment revealed a cell cycle-specific arrest,
leaving the physiological relevance of interaction be-
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(A) Structures of the immobilized ligands used for affinity chromatography.
(B) Synthetic scheme for the affinity resins.
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61tween Cdc28 and compound 1 unclear. Taken together,
the results of the overexpression screen are consistent
with the affinity chromatography experiment and sug-
gest that the growth-inhibitory effects of compound 1
are due to inhibition of Pkc1 and possibly also Cdc28.
In addition, biochemical experiments suggest that com-
pound 1 binds other cellular targets, which may con-
tribute to phenotypes observed in the dosage suppres-
sion screens.
Significance
In this study, a genome-wide yeast dosage suppres-
sion screen was used to identify the target of a PAP
compound with yeast growth-inhibitory activity. The
finding of Pkc1 as a target was confirmed by using
affinity chromatography and biochemical assays. The
high-throughput format of the screen is suitable for
a rapid follow-up study of a small-molecule screen,
particularly because imaging-based bioinformatics
can readily be implemented to facilitate data analysis.
Hits from small-molecule screens can putatively be
classified according to growth patterns on the agar
plates. As with any type of gene dosage-based experi-
ment, the screen selects not only for the drug target
but also for other members of the target pathway or
for genes that can confer resistance to the cell
through different mechanisms, including general
stress-response genes, drug efflux pumps, or meta-
bolic genes [45]. However, the array format repre-
sents an advantage over classical drug susceptibility
screens that employ pooled overexpression strains.
This format allows subtraction of nonspecific genes
identified previously without the need for repeated se-
quencing. Another advantage of the screen, espe-
cially when compared to screens utilizing deletion
strains, is that it can be easily repeated in different
genetic backgrounds such as yeast strains sensitized
to drugs through mutations in proteins affecting cell
permeability, therefore extending its utility to drugsTable 2. Inhibition of Mammalian Kinases In Vitro by Compounds
1 and 3 (IC50 Values)
Kinase Compound 1 CGP60474 (3)
PKC-α 2.2 M 0.25 M
CDK1/cycB 0.24 M 17 nM
CDK2/cycA n.d.a 80 nM
CDK5 0.12 M n.d.a
Assays were carried out by Novartis Pharma Inc., as described [24].
a n.d. = not determined.strains in the presence and absence of 1 (2% DMSO) were re-
(C) Silver-stained protein gel following affinity chromatography. Yeast protein extracts were loaded onto affinity matrices 4 and 5. After 1 hr
of incubation at 4°C under constant agitation and then three washes with bead buffer, bound proteins were extracted by boiling in SDS
sample buffer, resolved by SDS-PAGE (4%−20% Tris-glycine), and visualized by silver staining. For the competition assay (left lane), 100 M
compound 1 was present during the incubation and wash steps. Bands corresponding to proteins that bind specifically to resin 4 and
competed off by 1 are indicated.
(D) Immunoblot following affinity chromatography. Binding of Pkc1 and Cdc28 to resin 4 was assayed by Western blot analysis using goat
anti-Pkc1 and goat anti-Cdc28 polyclonal antibodies, respectively, and a rabbit anti-goat peroxidase-conjugated secondary antibody.
(E) In vitro kinase assay using the IQ PKC Assay kit with the pseudosubstrate peptide substrate (Pierce) and GST-Pkc1 (overexpressed in
yeast) in the presence of various concentrations of 1. Fluorescence at 590 nm was measured (excitation at 560 nm) and indicated the extent
of phosphorylation (inverse relationship).that are ineffective to wild-type yeast. Thus, the over-
expression screen is a useful complement to screens
exploiting homozygous or heterozygous deletion
strains to aid in target identification. Genetic screens
of this type may eventually be systematically transfer-
red to mammalian systems to probe more complex
pathways.
Experimental Procedures
Yeast Strains, Overexpression Library, and Media
The haploid S. cerevisiae strain YPH500 (MATa, ura3-52, lys2-801,
ade2-101, trp1-D63, his3-D200, leu2-D1) was used in minimal drop-
out media (−Leu) for both the small-molecule screen and genera-
tion of the overexpression library. The library was constructed in
YEp13 shuttle vectors (2 M LEU2) and was a gift from Dr. M.
Meijer, University Hospital Rotterdam, The Netherlands. YPH500
was transformed with the genomic DNA fragment library using the
standard lithium acetate procedure and individual colonies were
arrayed into 384-well plates containing minimal medium lacking
leucine. The homozygous and heterozygous deletion strains are
based on a BY4743 diploid strain background and were obtained
from Research Genetics (Invitrogen, Carlsbad, CA). Assays were
performed with synthetic complete medium. A yeast clone (Yeast
ExClone) containing a plasmid carrying the GST-Pkc1 encoding
gene under the control of the Cu2+-inducible CUP1 promoter was
obtained from Research Genetics (Invitrogen).
Small-Molecule Screen
In the primary screen, YPH500 cells (1 µl of a saturated culture
diluted 1:10) were spotted onto agar containing compounds at con-
centrations of 20 and 200 M in a 384-well format. Plates were
incubated for 3 days at 30°C and visually inspected for growth.
Hits were tested in dilution series to determine the minimal growth-
inhibitory concentration.
Overexpression Screen and Sequencing of Clones
Transformed yeast strains were grown on 384-well plates and repli-
cated onto −Leu agar plates containing the inhibitor (1536 strains
per plate) as described in the main text. Following 3-day incubation
at 30°C, hit colonies were picked, streaked onto −Leu agar plates,
and grown at 30°C. Subsequently, strains were grown overnight in
5 ml liquid cultures (−Leu) and yeast plasmid DNA was isolated as
follows. Cells were harvested by centrifugation (1000 × g) for 5 min
and the pellet was resuspended in 0.5 ml of 1 M sorbitol/0.1 M
EDTA (pH 8). Zymolyase (5 µl of 0.5 mg/ml 100T; ICN, Costa Mesa,
CA) was then added and the mixture was incubated at 37°C for 1
hr. Cells were centrifuged (1000 × g, 1 min) and plasmid DNA iso-
lated using the Spin Mini Prep kit (Qiagen, Valencia, CA) according
to the manufacturer’s protocol. E. coli KC8 cells were transformed
with the isolated yeast DNA (by electroporation) and plated on am-
picillin-containing LB plates. Colonies were grown in selective LB
medium (ampicillin, 100 g/ml), plasmid DNA was isolated as above,
and inserts were sequenced using primers DL1 (5#-ACTACG
CGATCATGGCGA-3#) and DL2 (5#-TGATGCCGGCCACGATGC-3#).
Deletion Strain Experiments
Growth curves of homozygous and heterozygous diploid deletion
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DIC50 values were determined based on cell growth after 20 hr by
monitoring the optical density at 600 nm (OD600). Values given in A
sFigure 3C correspond to concentrations at which the OD600
reached half of the maximum. a
Affinity Chromatography
SSynthesis of the linker derivatives and affinity supports is described
Gin the Supplemental Data. Yeast cells (YPH500) were grown in 1 L
mof YPDA medium (to OD600 0.8), harvested by centrifugation (1000 ×
gg, 5 min), and washed with 200 ml H2O and then with 200 ml break-
cage buffer (30 mM sodium phosphate [pH 7.0], 60 mM β-gly-
cerophosphate, 1 M KCl, 6 mM EDTA, 6 mM EGTA, 6 mM NaF, 10%
glycerol). Cells were resuspended in a minimal amount of breakage
buffer, protease inhibitors were added (1 mM PMSF, 10 g/ml each A
of leupeptin, pepstatin, and chemostatin), and cells were frozen in
liquid nitrogen. Frozen cells were ground with mortar and pestle F
while keeping the mortar cold. The cell powder was scraped into P
an Eppendorf tube, thawed, and pelleted in a microcentrifuge t
(14,000 × g, 15 min, 4°C). The supernatant was transferred into a H
new tube and pelleted again. The supernatant was aliquoted, fro- P
zen in liquid nitrogen, and stored at −80°C. Protein concentration s
was determined using the BCA protein quantification kit (Pierce,
Rockford, IL). The protein extract (400 g) was diluted into cold
R
bead buffer (50 mM Tris [pH 7.4], 5 mM NaF, 250 mM NaCl, 5 mM
R
EDTA, 5 mM EGTA, 0.1% Nonidet P-40, 100 M benzamidine) to a
A
total volume of 800 µl and added to 40 µl of affinity support (50%
P
slurry in PBS) that had been prewashed twice with bead buffer. The
mixture was incubated at 4°C for 1 hr under constant agitation, and
Rthereafter centrifuged (3000 × g, 1 min, 4°C). The supernatant was
discarded and the affinity support was washed three times with
cold bead buffer (in the competition assay, the buffer contained 100
M 1 during incubation and wash steps, final ethanol concentration
0.5%). After the final wash of the resin, 20 µl of SDS sample buffer
was added and the mixture was heated at 95°C for 5 min. Samples
were loaded onto a 4%–20% Tris-glycine SDS-polyacrylamide gel
(Invitrogen). Detection of protein bands was achieved by silver
staining using the Silver Stain Plus kit (Bio-Rad). For Western blot
analysis, proteins were transferred onto nitrocellulose membrane
by electrotransfer, and the membrane was blocked overnight at
4°C with 5% nonfat milk and then incubated with goat anti-Pkc1
(yC-20, 1:400) or goat anti-Cdc28 (yC-20, 1:200) polyclonal antibod-
ies (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr at room
temperature. The membrane was washed three times with PBS/
0.05% Tween 20 containing 5% nonfat milk, incubated with rabbit
anti-goat peroxidase-conjugated secondary antibody (1:5000;
Sigma, St. Louis, MO) for 1 hr at room temperature, washed with
PBS/0.05% Tween 20, and developed using the ECL plus Western
Blotting Detection system (Amersham Biosciences, Piscataway, NJ).
Protein Overexpression and Purification
The GST-Pkc1 fusion protein was purified from overexpressing
S. cerevisiae strain grown in 250 ml of −Ura −Leu medium. Protein
expression was induced by addition of CuSO4 to a final concentra-
tion of 0.5 mM in logarithmic phase (OD600 0.8) for 2 hr. Cells were
harvested by centrifugation, resuspended in 1 ml of lysis buffer (50
mM Tris-HCl [pH 7.5], 1 mM EDTA, 5 mM DTT, 10% glycerol, 1 M
NaCl, 1 mM phenylmethylsulfonyl fluoride, 2 g/ml each of leupep- 1
tin and pepstatin), and homogenized by vortexing in the presence
of glass beads. The lysis mixture was then pelleted, the superna-
tant was mixed with 2 ml of equilibrated 50% glutathione bead
slurry (Clontech, Palo Alto, CA), and incubated at 4°C for 1 hr. The
resin was washed with lysis buffer containing 1% Triton X-100 (3 × 1
4 ml) and the fusion protein was eluted with buffer containing 20
mM glutathione, 0.5 M NaCl, 50 mM Tris (pH 8), and dialyzed over-




The kinase assay was carried out using the IQ PKC Assay kit with
the pseudosubstrate peptide substrate (Pierce) in 96-well format
as recommended by the manufacturer. The assay mixture con- 1
tained w0.5 g GST-Pkc1, various concentrations of inhibitor 1 inMSO, 20 mM HEPES [pH 7.4], 1 mM CaCl2, 5 mM MgCl2, 1 mM
TT, 0.2 mg/ml phosphatidylserine, 60 M pseudosubstrate, 10 M
TP. The reaction was stopped after 2 hr by addition of IQ working
olution and fluorescence was measured at 590 nm with excitation
t 560 nm. No enzyme inhibition was seen at 1 mM ATP.
upplemental Data
eneral synthetic methods, selected spectroscopic data for inter-
ediates of affinity resin preparations, and structures of other yeast
rowth inhibitors are available online at http://www.chembiol.com/
gi/content/full/12/1/55/DC1/.
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